Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain surgery meets brain science: probing how a memory-related chemical system influences cognition

NCT ID NCT07721272

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study investigates how a drug called Cobenfy KarXT, which affects the brain's cholinergic (acetylcholine) system, alters brain activity during memory and thinking tasks. About 30 people with essential tremor or epilepsy who are already scheduled for deep brain stimulation (DBS) surgery will take either the drug or a placebo before their procedure. During awake surgery, researchers will use a clinical brain probe to record electrical signals while participants perform cognitive tasks, aiming to understand how cholinergic circuits support learning, memory, and cognitive control.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cobenfy KarXT (xanomeline-trospium) pill or placebo, given once before surgery
What this could lead to
If it works, this could reveal how the brain's cholinergic system supports memory and decision-making, pointing toward new treatments for cognitive disorders.
What could go wrong
This is a very early, small study (30 people) focused on measuring brain signals, not treating disease. Results may not apply to broader populations or lead directly to therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Study Population Inclusion Criteria for Essential Tremor Patients: * Diagnosis of Essential Tremor * Recommended to undergo deep brain stimulation implantation surgery for surgical management of medication-resistant tremor based on clinical indications Exclusion Criteria for Essential Tremor Patients: * Patients with recent use (within one week) of anticoagulant or antiplatelet agent * Contraindication to use of cholinergic modulation Inclusion Criteria for Epilepsy Patients * Diagnosis of intractable epilepsy * Undergoing neuromodulation procedure that utilizes insertion of electrodes into subcortical structures, including the thalamus or hippocampus * Undergoing neuromodulation procedure that utilizes frame-based insertion of electrodes into the thalamus (ANT or CM) Exclusion Criteria for Epilepsy Patients: * Patients with recent use (within one week) of anticoagulant or antiplatelet agent * Contraindication to use of cholinergic modulation Contraindication for cholinergic modulation in both patient sets will be assessed by members of the treatment team (e.g. epileptologist), as well as a neuroanesthesiologist. Multiple medications and conditions are singular disqualifiers; however some medications are eliminated only in combination following neuroanesthesiologist evaluation. Patients at risk of reaction to the treatment arm based on concurrent or recent medications or other health conditions will be excluded from participation. Inclusion Criteria for Study Participation * Is patient between 18-70? * In general good health, aside from history of epilepsy or essential tremor, as ascertained by medical history, physical exam, clinical labs, and ECG? * Candidate for surgery as determined independently by the patient's treating physician/clinical team as part of the patient's routine medical care? * Able to read, understand, and provide written, dated informed consent, and participate in cognitive tasks? Exclusion Criteria for Study Participation * Female that is pregnant, breastfeeding, or has a positive pregnancy test? * Under 18, over 70, or currently a prisoner on medical release? * Hepatic impairment (moderate or severe)? * Renal impairment (moderate or severe)? * Untreated narrow angle glaucoma? * Bladder obstruction, prostatic hyperplasia (BPH), diabetic cystopathy, pre-existing urinary retention? * History of hypersensitivity to COBENFY or trospium chloride? * Biliary disease, including symptomatic gallstones, gallbladder disorders, pancreatitis? * Fluoxetine, paroxetine, bupropion, terbinafine? * Buspirone or eletriptan? * Digoxin, colchicine, apixaban? * Diphenhydramine, beztropine, oxybutynin? * Benztropine, trihexyphenidyl, tolterodine, solifenacin, darifenacin, fesoterodine, hyoscyamine, dicyclomine, scopolamine?

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cognitive control are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.